Equine Aβ40 antibody and antigen (recombinant protein)

Diagnostic anti-Equine Aβ40 antibodies pairs and antigen for animal health (animal Equine/Horse Alzheimer Disease(AD)) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT

Target products collectionGo to Equine disease testing products collection >>


Product information

Catalog No.DescriptionUS $ Price (per mg)
GMP-EQU-AB40-Ag01Equine Aβ40$3090.00
GMP-EQU-AB40-Ab01Anti-Equine Aβ40 mouse monoclonal antibody (mAb)$3090.00
GMP-EQU-AB40-Ab02Anti-Equine Aβ40 mouse monoclonal antibody (mAb)$3090.00
GMP-EQU-AB40-Ab03Anti-Equine Aβ40 human monoclonal antibody (mAb)$3090.00
GMP-EQU-AB40-Ab04Anti-Equine Aβ40 human monoclonal antibody (mAb)$3090.00

Size： 1mg | 10mg | 100mg



Product Description

Cat No. GMP-EQU-AB40-Ag01
Product NameEquine Aβ40
Target/BiomarkerEquine Aβ40
Expression platformE.coli
IsotypesRecombinant Antigen
Bioactivity validationAnti-Equine Aβ40 antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Aβ40 level test of animal Equine/Horse with Alzheimer Disease(AD).
TagHis
Reconized/Reactive SpecicsEquine Aβ40
Product descriptionRecombinant Equine Aβ40 protein was expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
PurityPurity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Cat No.GMP-EQU-AB40-Ab01,GMP-EQU-AB40-Ab02
Target/BiomarkerEquine Aβ40
Product NameAnti-Equine Aβ40 mouse monoclonal antibody (mAb)
Expression platformCHO
Isotypes Mouse IgG
Bioactivity validationRecombinant Equine Aβ40 antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine Aβ40 antibodies in Equine Aβ40 level test of animal Equine/Horse with Alzheimer Disease(AD).
Product descriptionAnti-Equine Aβ40 mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine Aβ40 antibodies.
PurityPurity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Cat No.GMP-EQU-AB40-Ab03,GMP-EQU-AB40-Ab04
Target/BiomarkerEquine Aβ40
Product NameAnti-Equine Aβ40 human monoclonal antibody (mAb)
Expression platformCHO
IsotypesHuman lgG1
Bioactivity validationRecombinant Equine Aβ40 antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine Aβ40 antibodies in Equine Aβ40 level test of animal Equine/Horse with Alzheimer Disease(AD).
Product descriptionAnti-Equine Aβ40 mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair.
PurityPurity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Reference




    Validation Data


    Click to get more Data / Case study about the product.



    Target/Biomarker Information


    Equine Amyloid-beta 40 (Aβ40) is a remarkable molecule in equine neuroscience, occupying a central role in our understanding of neurodegenerative conditions affecting our noble equine companions. Comprising 40 amino acids, Aβ40 is a fragment of the amyloid precursor protein (APP) and stands as a critical component in the formation of amyloid plaques within the equine brain. These plaques, primarily composed of Aβ40, have come to symbolize cognitive decline in horses, most notably in cases of equine cognitive dysfunction syndrome (ECDS).

    The genesis of Aβ40 involves proteolytic cleavage of APP, a process mediated by β-secretase and γ-secretase enzymes. In horses afflicted by ECDS, a perturbation in Aβ40 metabolism and clearance results in its aggregation, leading to the accumulation of amyloid plaques. These plaques disrupt normal neuronal function, contributing substantially to the cognitive deficits seen in affected horses.

    The ramifications of Aβ40 aggregation extend further, encompassing a cascade of deleterious effects. These include neuroinflammation, oxidative stress, and synaptic dysfunction, all of which collectively contribute to the progressive cognitive deficits witnessed in horses suffering from ECDS.



    About GDU


    GDU

    GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.